Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Phase II Randomized Study of Brain-directed Stereotactic Radiation With or Without AGuIX Gadolinium-based Nanoparticles in the Management of Brain Metastases at Higher Risk of Local Recurrence With Radiation Alone

NCT04899908 is registered in ClinicalTrials.gov with Brigham and Women's Hospital as lead sponsor.

NCT NCT04899908
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04899908 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Phase II Randomized Study of Brain-directed Stereotactic Radiation With or Without AGuIX Gadolinium-based Nanoparticles in the Management of Brain Metastases at Higher Risk of Local Recurrence With Radiation Alone
Lead sponsor
Brigham and Women's Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
September 15, 2021
Completion date
May 31, 2029
Enrollment
134 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

aguix, brain cancer, brain metastases, brain tumor, breast cancer, colorectal cancer, cystic, gastrointestinal cancer, her2-positive breast cancer, lung cancer, melanoma, nanoparticle, srs, srt, stereotactic radiation, whole brain radiation